Streetbeat News

Products Services

ASTS

AST SpaceMobile, Inc. (NASDAQ:ASTS) shares are experiencing volatility after rising on Thursday. The company announced that certain shareholders may attend the launch of the BlueBird 1-5 Mission at Cape Canaveral. The BlueBird satellites are part of AST SpaceMobile's mission to create the first global cellular broadband network in space. Analysts from B. Riley Securities and UBS have raised their price targets for ASTS.

Portfolio Pulse from Dylan Berman

August 16, 2024 | 6:15 pm

CDNA

CareDx announced that the Centers for Medicare & Medicaid Services (CMS) has retired a draft policy that would have restricted coverage for its AlloSure, AlloMap, and HeartCare tests. The longstanding coverage for these tests, which are used for surveillance testing for allograft rejection, has been restored.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 6:11 pm

Richtech Robotics has teased an upcoming announcement on social media, hinting at a new development or product. The company posted on X, 'Something new is coming!!! Can you guess what?'

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 6:07 pm

LLY

NVO

Doctors are facing challenges in securing Medicare coverage for Novo Nordisk's weight-loss drug Wegovy, despite its potential benefits for heart patients. Medicare's legal restrictions on covering weight-loss drugs and the high cost of Wegovy are significant barriers. Novo Nordisk is working with policymakers to improve coverage, and there is hope for better coverage next year. Eli Lilly's obesity drug Zepbound may also impact the market if it gains FDA approval for treating obstructive sleep apnea.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:59 pm

ORGN

Origin Materials, Inc. (NASDAQ:ORGN) shares surged after reporting Q2 financial results. Despite missing earnings and sales estimates, the company secured a 2-year MOU for PET closure production, projected to generate over $100 million in revenue starting in 2025. BofA Securities upgraded ORGN to Buy, raising the price target to $3.00, citing potential profitability as early as 2026 and significant long-term growth potential in its biomass conversion technology.

Portfolio Pulse from Lekha Gupta

August 16, 2024 | 5:58 pm

LLY

NVO

RHHBY

Roche missed out on acquiring a potential blockbuster weight-loss drug, orforglipron, which Eli Lilly acquired for $50 million and is projected to generate up to $14 billion annually by 2032. Roche's cautious approach, influenced by past setbacks, led to this missed opportunity. Roche re-entered the obesity market in 2023 but is expected to lag behind competitors like Eli Lilly and Novo Nordisk.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:56 pm

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) shares surged by 65.4% following the WHO's declaration of mpox as a global health emergency and the ECDC's new risk assessment. The ECDC recommends heightened preparedness and rapid response measures in the EU/EEA due to the risk of imported mpox cases from Africa.

Portfolio Pulse from Vaishali Prayag

August 16, 2024 | 5:40 pm

AMAT

AMCR

COHR

DIA

FLO

GDX

GLOB

HRB

IWM

MRVI

QQQ

RGEN

SPY

XLC

XLF

XLRE

XLY

Wall Street saw modest gains on Friday, driven by improved consumer sentiment and strong economic data. Gold hit a record high, boosting mining stocks, while oil prices dipped due to geopolitical developments. Key ETFs and stocks showed varied performances, with notable movements in H&R Block, Amcor, Applied Materials, Coherent, Flower Foods, Globant, and Repligen.

Portfolio Pulse from Piero Cingari

August 16, 2024 | 5:38 pm

AAPL

AMD

DELL

INTC

MCHP

MSFT

NVDA

PLTR

SKYT

TSM

The article highlights significant options activity in the Information Technology sector, focusing on trades involving companies like AAPL, MSFT, NVDA, AMD, INTC, TSM, DELL, SKYT, PLTR, and MCHP. These activities could indicate potential trading opportunities based on the sentiment and volume of the trades.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:35 pm

TNXP

Tonix Pharmaceuticals' live virus vaccine candidate, TNX-801, shows long-term protection from mpox and smallpox with a single dose in animal studies. The company is advancing its development, and the vaccine has been selected by the NIH for Project NextGen. The stock saw a 4.01% increase, trading at $0.48.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:29 pm